Liposomal Drug Delivery of a Major Component of Coconut Oil for the Treatment of Acne Vulgaris in vitro and in vivo

  • Dissaya Pornpattananangku
Keywords: Free fatty acid, coconut oil, lauric acid, antimicrobial, drug delivery, liposome, in vivo


Abundantly found in coconut oil, lauric acid (LA), a 12-carbon atom chain free fatty acid, has shown its potent antimicrobial activity against the acne-causing bacteria, Propionibacterium acnes (P. acnes). To facilitate the administration of LA and improve its efficacy, nanoliposomes were used to encapsulate LA. In this study, the antimicrobial activity of LA was compared with other free fatty acids and benzoyl peroxide (BPO). Subsequently, LA was incorporated into nano-sized bilayer lipid vesicle (lauric acid liposome, LipoLA). It was demonstrated that the antimicrobial activity of LA in LipoLA was enhanced at low LA concentration. Interaction study also showed that the liposome aids in the fusion between LA and the bacterial membrane, leading to an effective delivery of LA molecules to the target site. More interestingly, in vivo study indicates that antimicrobial activity of LipoLA is well preserved and higher than BPO. Since LA is a natural compound from coconut oil and liposomes have been successfully and widely applied as a drug delivery vehicle in the clinic, the LipoLA developed in this work holds great potential of becoming a safe and effective therapeutic medication for acne vulgaris and other P. acnes associated infections.

Author Biography

Dissaya Pornpattananangku

Department of Chemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok, 10330 Thailand


Beaulac, C., S. Sachetelli, and J. Lagace, In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria. J Antimicrob Chemother, 1998. 41(1): p. 35-41.
Biju, S.S., A. Ahuja, and R.K. Khar, Tea tree oil concentration in follicular casts after topical delivery: determination by high-performance thin layer chromatography using a perfused bovine udder model. J Pharm Sci, 2005. 94(2): p. 240-5.
Bhalerao, S.S. and A. Raje Harshal, Preparation, optimization, characterization, and stability studies of salicylic acid liposomes. Drug Dev Ind Pharm, 2003. 29(4): p. 451-67.
Bojar, R.A. and K.T. Holland, Acne and Propionibacterium acnes. Clin Dermatol, 2004. 22(5): p. 375-9.
Bruggemann, H., et al., The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science, 2004. 305(5684): p. 671-3.
Burkhart, C.G., C.N. Burkhart, and P.F. Lehmann, Acne: a review of immunologic and microbiologic factors. Postgrad Med J, 1999. 75(884): p. 328-31.
Fried, R.G. and A. Wechsler, Psychological problems in the acne patient. Dermatol Ther, 2006. 19(4): p. 237-40.
Ha, T., Single-molecule fluorescence resonance energy transfer. Methods, 2001. 25(1): p. 78-86.
Honzak, L. and M. Sentjurc, Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Pflugers Arch, 2000. 440(5 Suppl): p. R44-5.
Kim, J., Review of the innate immune response in acne vulgaris: activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology, 2005. 211(3): p. 193-8.
Lieb, L.M., et al., Topical delivery enhancement with multilamellar liposomes into pilosebaceous units: I. In vitro evaluation using fluorescent techniques with the hamster ear model. J Invest Dermatol, 1992. 99(1): p. 108-13.
Mezei, M. and V. Gulasekharam, Liposomes-a selective drug delivery system for the topical route of administration: gel dosage form. J Pharm Pharmacol, 1982. 34(7): p. 473-4.
Nakatsuji, T., et al., Antimicrobial property of lauric acid against propionibacterium acnes: Its Therapeutic Potential for Inflammatory Acne Vulgaris. J Invest Dermatol, 2009. 129(10): p. 2480-8.
Nakatsuji, T., et al., Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. J Invest Dermatol. 130(4): p. 985-94.
Pornpattananangkul, D., et al., In vivo treatment of Propionibacterium acnes infection with liposomal lauric acids. Adv Healthcare Mater, 2013. 2(10): p. 1322-1328.
Schmid, M.H. and H.C. Korting, Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Delivery Rev, 1996. 18(3): p. 335-342.
Taglietti, M., C.N. Hawkins, and J. Rao, Novel topical drug delivery systems and their potential use in acne vulgaris. Skin Therapy Lett, 2008. 13(5): p. 6-8.
Verma, D.D., et al., Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm, 2003. 258(1-2): p. 141-51.
Webster, G.F. and J.J. Leyden, Characterization of serum-independent polymorphonuclear leukocyte chemotactic factors produced by Propionibacterium acnes. Inflammation, 1980. 4(3): p. 261-9.
Yang, D and Pornpattananangkul, D., et al., The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials, 2009. 30(30): p. 6035-6040.
How to Cite
Dissaya Pornpattananangku. (2016). Liposomal Drug Delivery of a Major Component of Coconut Oil for the Treatment of Acne Vulgaris in vitro and in vivo. CORD, 32(1), 9.